ABIO ARCA biopharma Inc

Price (delayed)

$2.48

Market cap

$35.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.3

Enterprise value

-$12.96M

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically ...

Highlights
ARCA biopharma's EPS has increased by 35% YoY and by 6% from the previous quarter
The company's debt fell by 9% YoY and by 7% QoQ
ARCA biopharma's net income has decreased by 48% YoY but it has increased by 4.3% QoQ
The company's quick ratio fell by 22% YoY but it rose by 18% QoQ
The company's equity fell by 27% YoY and by 6% QoQ

Key stats

What are the main financial stats of ABIO
Market
Shares outstanding
14.41M
Market cap
$35.74M
Enterprise value
-$12.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$18.49M
EBITDA
-$18.39M
Free cash flow
-$17.87M
Per share
EPS
-$1.3
Free cash flow per share
-$1.24
Book value per share
$3.33
Revenue per share
$0
TBVPS
$3.54
Balance sheet
Total assets
$51.01M
Total liabilities
$3.08M
Debt
$357,000
Equity
$47.94M
Working capital
$47.82M
Liquidity
Debt to equity
0.01
Current ratio
18.59
Quick ratio
18.04
Net debt/EBITDA
2.65
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-32%
Return on equity
-34.1%
Return on invested capital
N/A
Return on capital employed
-38.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABIO stock price

How has the ARCA biopharma stock price performed over time
Intraday
-1.98%
1 week
5.53%
1 month
7.87%
1 year
-29.94%
YTD
15.35%
QTD
7.83%

Financial performance

How have ARCA biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.51M
Net income
-$18.49M
Gross margin
N/A
Net margin
N/A
ARCA biopharma's net income has decreased by 48% YoY but it has increased by 4.3% QoQ
ABIO's operating income is down by 48% year-on-year but it is up by 4.3% since the previous quarter

Growth

What is ARCA biopharma's growth rate over time

Valuation

What is ARCA biopharma stock price valuation
P/E
N/A
P/B
0.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARCA biopharma's EPS has increased by 35% YoY and by 6% from the previous quarter
The company's equity fell by 27% YoY and by 6% QoQ
ABIO's price to book (P/B) is 16% lower than its 5-year quarterly average of 0.9 but 9% higher than its last 4 quarters average of 0.7

Efficiency

How efficient is ARCA biopharma business performance
The return on equity has declined by 18% year-on-year and by 3.6% since the previous quarter
ARCA biopharma's return on assets has decreased by 17% YoY and by 3.2% QoQ

Dividends

What is ABIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABIO.

Financial health

How did ARCA biopharma financials performed over time
The company's total assets fell by 26% YoY and by 7% QoQ
The company's current ratio fell by 22% YoY but it rose by 19% QoQ
The company's debt is 99% lower than its equity
The company's equity fell by 27% YoY and by 6% QoQ
The company's debt fell by 9% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.